HESTERBIO

Hester Biosciences Share Price

₹1,843.50 +24.3 (1.34%)

20 May, 2025 01:41

SIP TrendupStart SIP in HESTERBIO

Start SIP

Performance

  • Low
  • ₹1,836
  • High
  • ₹1,874
  • 52 Week Low
  • ₹1,243
  • 52 Week High
  • ₹3,379
  • Open Price₹1,849
  • Previous Close₹1,819
  • Volume5,167

Investment Returns

  • Over 1 Month + 3.87%
  • Over 3 Month + 15.72%
  • Over 6 Month -24.18%
  • Over 1 Year + 4.67%
SIP Lightning

Smart Investing Starts Here Start SIP with Hester Biosciences for Steady Growth!

Invest Now

Hester Biosciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 57.1
  • PEG Ratio
  • 1.3
  • Market Cap Cr
  • 1,568
  • P/B Ratio
  • 5.2
  • Average True Range
  • 96.57
  • EPS
  • 32.31
  • Dividend Yield
  • 0.3
  • MACD Signal
  • 36.4
  • RSI
  • 57.97
  • MFI
  • 38.06

Hester Biosciences Financials

Hester Biosciences Technicals

EMA & SMA

Current Price
₹1,843.50
+ 24.3 (1.34%)
pointer
  • stock-down_img
  • Bearish Moving Average 3
  • stock-up_img
  • Bullish Moving Average 13
  • 20 Day
  • ₹1,768.04
  • 50 Day
  • ₹1,740.86
  • 100 Day
  • ₹1,837.90
  • 200 Day
  • ₹1,954.72

Resistance and Support

1851.17 Pivot Speed
  • R3 1,904.33
  • R2 1,889.17
  • R1 1,866.33
  • S1 1,828.33
  • S2 1,813.17
  • S3 1,790.33

What's your outlook on Hester Biosciences?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Hester Biosciences Ltd. is a leading manufacturer of animal healthcare products, specializing in vaccines and veterinary pharmaceuticals. With production facilities in India and Nepal, it serves domestic and international markets, focusing on livestock and poultry healthcare solutions.

Hester Biosciences has an operating revenue of Rs. 311.10 Cr. on a trailing 12-month basis. An annual revenue de-growth of 0% needs improvement, Pre-tax margin of 11% is healthy, ROE of 8% is fair but needs improvement. The company has a reasonable debt to equity of 42%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and around 12% up from its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 44 which is a POOR score indicating inconsistency in earnings, a RS Rating of 41 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 51 indicates it belongs to a fair industry group of Medical-Ethical Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Hester Biosciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-09 Audited Results & Final Dividend
2025-01-30 Quarterly Results
2024-10-28 Quarterly Results
2024-08-02 Quarterly Results
2024-05-10 Audited Results & Dividend

Hester Biosciences F&O

Hester Biosciences Shareholding Pattern

53.73%
0%
0.87%
32.64%
12.76%

About Hester Biosciences

  • NSE Symbol
  • HESTERBIO
  • BSE Symbol
  • 524669
  • Managing Director & CEO
  • Mr. Rajiv Gandhi
  • ISIN
  • INE782E01017

Similar Stocks to Hester Biosciences

Hester Biosciences FAQs

Hester Biosciences share price is ₹1,843 As on 20 May, 2025 | 01:27

The Market Cap of Hester Biosciences is ₹1568.2 Cr As on 20 May, 2025 | 01:27

The P/E ratio of Hester Biosciences is 57.1 As on 20 May, 2025 | 01:27

The PB ratio of Hester Biosciences is 5.2 As on 20 May, 2025 | 01:27

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23